Full-Time

Executive Director

Therapeutic Area Operations Leader-Obesity, Muscle, Metabolism

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops medicines for serious diseases

Biotechnology
Healthcare

Compensation Overview

$281.4k - $468.9kAnnually

Senior, Expert

Westchester County, NY, USA + 2 more

More locations: Uxbridge, UK | Berkeley Heights, NJ, USA

Hybrid position requiring 3 days in-office and 2 days from home.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Risk Management
Google Cloud Platform

You match the following Regeneron Pharmaceuticals's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • A Bachelors degree, an advanced degree is highly desirable.
  • 15+ years’ experience of clinical operations experiences in a pharmaceutical or biotech setting with:
  • 10+ years of functional leadership, 10+ years people management, leadership and mentoring experience, 5+ years of leading complex, global clinical trials with outsourced CRO/FSP model(s)
  • Obesity, Muscle, and Metabolism expertise is a must
  • In depth knowledge of GCP and ICH, drug development process, and other relevant guidelines for clinical research activities
  • Experience leading global clinical research activities
  • Exceptional project management, cross-functional team leadership and organizational skills
  • Ability to make decisions, set priorities, and share resources based upon an enterprise mindset, ensuring the benefit to the whole organization. Ability to leverage network to understand the big picture, perspectives, and expertise to maximize performance
  • Ability to provide strategic direction, guidance, and timely decision-making for program teams; ability to capitalize on opportunities and manage risk
  • Ability to anticipate and react to new trends in a competitive landscape and therapeutic areas to guide the organizational strategy
  • Ability to 25% travel
Responsibilities
  • Partner with the Therapeutic Area Head and Global Program Heads, meets regularly to review TA progress and project status
  • Responsible and accountable for the successful operational delivery of all studies in the TA within the Clinical Development Plan (CDP)
  • Contribute functional area expertise to the development of the program and clinical trial operational strategy (e.g., feasibility, timelines, cost estimates) and participates actively at strategy committees (e.g. Development Program Review and Protocol Review)
  • Ensure delivery of quality operational deliverables while ensuring consistency of process and approaches across clinical programs within and across TAs and facilitates streamlined processes across CTM TA Operations leadership
  • Identify and implement opportunities for innovation within clinical trial operations and identifies trends or competitors in disease area landscape to guide operational strategy
  • Liaise closely with the Therapeutic Area Head (TAH), Development Portfolio Management (DPM) and Strategic Program Direction to ensure clinical study deliverables support clinical program goals and project execution
  • Provide consolidated analysis of Key Performance Indicators (KPI) and operational metrics within the assigned TA and developing/managing appropriate action plans
  • Provide input into risk management strategy for clinical study teams and ensuring execution against the risk management plan.
  • Oversee CRO partnership related to delivery of outsourced services, including ensuring that CTM staff provide an appropriate and documented level of oversight for site/CRO/vendor services
  • Actively participate in appropriate governance meetings and acts as representative for CTM in CRO Joint Oversight Committees
  • Interface with senior management to report on milestones including Clinical Operations Review meetings
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its development efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and licensing its technologies. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring that its products meet high safety and efficacy standards.

Company Size

10,001+

Company Stage

IPO

Total Funding

$684M

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA priority review of Dupixent could expand Regeneron's dermatology market share.
  • Growing antibody therapy market offers lucrative opportunities for Regeneron's products.
  • Collaboration with Axelia Oncology enhances Regeneron's oncology portfolio.

What critics are saying

  • Increased competition in monoclonal antibodies may impact Regeneron's market share.
  • Class action lawsuit could lead to financial liabilities and reputational damage.
  • Significant investment in Truveta may not yield expected returns if challenges arise.

What makes Regeneron Pharmaceuticals unique

  • Regeneron leads in genomic research through the Truveta Genome Project.
  • The company has a strong focus on monoclonal antibody therapies.
  • Regeneron collaborates with academic and research institutions for cutting-edge advancements.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PharmiWeb
Feb 18th, 2025
Dupixent Sbla Accepted For Fda Priority Review For The Targeted Treatment Of Bullous Pemphigoid

If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision expected by June 20, 2025Priority review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placeboBP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesionsParis and Tarrytown, NY, February 18, 2025. The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).The sBLA is supported by data from a pivotal study evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe BP. The primary endpoint was met, with five times more Dupixent patients achieving sustained disease remission compared to those on placebo. Sustained disease remission was defined as complete clinical remission with completion of oral corticosteroids (OCS) taper by week 16 (off OCS treatment and only treated with Dupixent for at least 20 weeks) without relapse and no rescue therapy use during the 36-week treatment period. The study also showed that Dupixent significantly reduced disease severity, itch, and use of OCS compared to placebo.Adverse events more commonly observed with Dupixent (in at least 3 patients) compared to placebo included peripheral edema, arthralgia, back pain, blurred vision, hypertension, asthma, conjunctivitis, constipation, upper respiratory tract infection, limb injury, and insomnia.BP is a chronic, debilitating, and relapsing skin disease with underlying type-2 inflammation that typically occurs in an elderly population. It is characterized by intense itch and blisters, reddening of the skin, and painful lesions

MarketBeat
Feb 18th, 2025
ABC Arbitrage SA Makes New $1.51 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ABC Arbitrage SA makes new $1.51 million investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Brandon Capital
Feb 17th, 2025
Axelia Oncology Announces a Clinical Supply Agreement with Regeneron for Trial Evaluating AXA-042 in Combination with Libtayo(R) (cemiplimab)

Axelia Oncology announces a clinical supply agreement with Regeneron for trial evaluating AXA-042 in combination with Libtayo(R) (cemiplimab).

MarketBeat
Feb 15th, 2025
Warther Private Wealth LLC Invests $3.32 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Warther Private Wealth LLC invests $3.32 million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

PharmiWeb
Jan 29th, 2025
Antibody Therapy Market To Surge, Expected To Reach Usd 824 Billion By 2033 At A 13.4% Of Cagr

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of 13.4% from 2023 to 2033. With a valuation of USD 235 billion in 2023, the market is expected to surpass USD 824 billion by the end of the forecast period, driven by advancements in monoclonal antibody therapies and increasing demand for targeted treatments.The growing preference for protein-based, non-chemical treatments has fueled the adoption of monoclonal antibody therapy, particularly for cancer and cell-based diseases. Enhanced research and development efforts, supported by government funding, are further strengthening the effectiveness and accessibility of these treatments. Additionally, the expansion of cancer-specialized hospitals is boosting demand for antibody therapies.The market saw a significant boost during the COVID-19 pandemic, with the FDA approving advanced antibody therapies for treatment, leading to an accelerated CAGR of 18.2% between 2017 and 2022. As immunotherapy and chemotherapy resistance challenges continue, monoclonal antibodies have emerged as a promising alternative due to their high efficacy and reduced side effects.Request a Sample Report Now to get Premium Insights: https://www.futuremarketinsights.com/report-sample#5245502d47422d3134333632Key Takeaways:The antibody therapy market is set to grow from USD 235 billion in 2023 to USD 824 billion by 2033 at a CAGR of 13.4%.Rising cancer prevalence, regulatory approvals, and R&D collaborations are key growth drivers.Monoclonal antibodies offer a promising alternative to traditional chemotherapy, addressing tumor resistance and reducing side effects.Increased demand for targeted therapies and expanded healthcare infrastructure are expected to fuel long-term market growth.Key Growth DriversIncreasing Prevalence of Chronic Diseases The rising incidence of chronic diseases, particularly cancer and autoimmune disorders, is a significant driver for the antibody therapy market. As these conditions become more prevalent, the demand for effective treatment options, such as monoclonal antibodies, increases